Eslam Elkhadrawy/LinkedIn
Jan 28, 2026, 11:45
Eslam Elkhadrawy on Heparin-Induced Thrombocytopenia
Eslam Elkhadrawy, Product Specialist at Inspire Pharma Egypt, shared on LinkedIn:
”Heparin-Induced Thrombocytopenia (HIT):
When anticoagulation paradoxically causes thrombosis
HIT is a severe immune-mediated adverse drug reaction in which heparin exposure leads to thrombocytopenia accompanied by a high risk of thrombosis, rather than bleeding.
The condition is driven by IgG antibodies against the heparin–platelet factor 4 (PF4) complex, resulting in platelet activation and excessive thrombin generation.
Key message:
In HIT, thrombocytopenia reflects platelet activation and consumption, not impaired hemostasis.
References
Greinacher A. NEJM, 2015
Warkentin TE. Circulation, 2015”
Stay updated with Hemostasis Today.
-
Apr 26, 2026, 07:10Mouna Sassi: Viscoelastic Evidence of Altered Clot Stability in Pediatric Edoxaban Overdose
-
Apr 26, 2026, 07:02Matías J. Alet: Reflections on Stroke Care and Brain-Heart Interaction at Stroke Congress 2026
-
Apr 26, 2026, 06:53Azizah Zakaria: Stroke Guard’s Journey – From Student Innovation to Award-Winning Impact
-
Apr 26, 2026, 06:45Ifeanyichukwu Ifechidere: Developing Diagnostic Reasoning in Coagulation Testing
-
Apr 26, 2026, 06:33Ellen Norris: 2025 Premier Award Honors Contributions to the Hemophilia Community
-
Apr 26, 2026, 06:32Flavia Evangeline: Acute Heat Stroke Care – Nursing Role in Prevention of Organ Failure and Death
-
Apr 26, 2026, 06:28Brian Mahony: Real-World Positioning of Rebalancing Agents
-
Apr 26, 2026, 06:24Tamarra Crandall: A Heart Walk Honoring My Mother and All Lives Affected by Stroke
-
Apr 26, 2026, 06:20Jim Hoffman: The Role of Neutrophil Extracellular Traps in Central Nervous System Infections